The 0.75 percent and 0.25 percent updates to the CY 2026 qualifying APM and APM and nonqualifying APM conversion factors, respectively, as well as the single year increase of 2.50 percent to the conversion factor for CY 2026, are statutory changes that take place outside of BN, and therefore, are not captured in the specialty impacts displayed in Table D-B7
There, it plays a part in restoring and regenerating cells
If a pharmacy or compounding facility hands you a different syringe type, ask the prescriber to convert the dose to that syringes markings in writing before the first injection
In sections V.B.5.c.(3), V.B.5.c.(4), and V.B.5.c.(5) of this final rule, we detail the estimated burden changes per collection type for traditional MIPS, and in section V.B.5.c.(6) for MVPs finalized in this rulemaking
July 23-24, 2026 FDA meeting: The Pharmacy Compounding Advisory Committee will formally review BPC-157 (free base and acetate salt), KPV, TB-500, and MOTS-c at the FDA White Oak Campus
